SFI-CAST forskere, Ola Myklebost, Gustav Gaudernack (tidligere medl), Therese Sørlie i VG 28.april

"Nytt håp for kreftpasienter"

Ola Myklebost intervjuet i VG.

Therese Sørlie (SFI-CAST) was granted an extended research stipend from Helse Sør-Øst for 2012. These types of fellowships were granted for the first time and includes up to 2 mill NKR for four years.

In January, Hanne Røberg-Larsen (SFI-CAST) was recently awarded the GE Healthcare Young Scientist award, for her Master thesis entitled “Determination of oxysterols in cancer stem cells using on-line automated filtration and filter-flush solid phase extraction liquid chromatography tandem mass spectrometry”.  In addition to this achievement, Hanne has had a good year in 2011; In January, she was awarded the Water Innovation Prize, for her lecture on analysis of oxysterols using “AFFL-SPE-LC”, a technique that she and two other co-inventors (Kristin Svendsen and supervisor Steven Ray Wilson) have applied for a patent together with Inven2. Also, she is second author of a paper that was published this summer, and first author on a paper recently submitted.  Hanne was supervised by Steven Ray Wilson, Elsa Lundanes, Tyge Greibrokk and Stefan Krauss.

Dr. Pål Selbo was interviewed in connection with the European Cancer Organization (ECCO) in Stockholm, September 24th. The interview was published on ecancer.tv and was rated as "editors pick" in the "Technologies" category.

ODIN Therapeutics AS recently announced the achievement of clinical candidate stage for its lead inhibitor of canonical Wnt signaling. “The success of ODIN Therapeutics AS shows that the concept of...

SFI-CAST successfully passed the midterm evaluation by an international expert panel and receives full funding for its second term. "We are very pleased about the continued support...

A new universal cancer vaccine will be put on trial for testing on humans next year. The aim of the vaccine is to trigger the immune system to recognize the enzyme telomerase, which is over-produced by cancer cells and is responsible for ensuring that cancer cells can divide indefinitely (cell immortalization). Telomerase is an enzyme that is not expressed (shut off) in normal cells, thus only the cancer cells will be attacked, explains professor Gustav Gaudernack. Gaudernack, together with Anne-Marie Rasmussen and Else Marit Inderberg Suso, has been responsible for the research that led to the development of this vaccine. 

At the symposium for Mass Spectrometry 2011 Hafjell, Master student Hanne Roberg Larsen's presentation won the Waters Innovation Prize ($25.000 in instrumentation and services).

There are no available positions at the moment.